Drug Profile
Mesenchymal stem cell therapy - Medipost
Alternative Names: Bonestem; Heartstem; PromostemLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Medipost
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Bone disorders; Myocardial infarction
- Discontinued Glioma; Graft-versus-host disease
Most Recent Events
- 17 Aug 2012 Medipost's Mesenchymal stem cell therapy is available for licensing. http://www.medi-post.co.kr
- 12 Jun 2012 No development reported - Preclinical for Bone disorders in South Korea (Parenteral)
- 12 Jun 2012 No development reported - Preclinical for Myocardial infarction in South Korea (Parenteral)